30 closest matches · ranked by relevance
Post-stroke Spasticity of the Lower Limb
Primary: Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4 — 2.8; 2.8; -0.4; -0.4 Units on a scale — p=0.777
Lower Limb Spasticity Due to Cerebral Palsy
Primary: Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle (1st IC) — -0.7; -0.66…
Multiple Sclerosis
Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale
Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy
Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) Overall and Per Injection Cycle — 53; 44; 26; 31 participants
Transcutaneous Spinal Stimulation · Walking · Spasticity
Primary: Change in Walking Function - 10m Walk Walking Speed (m/s) — 0.06; 0.16 speed difference in meters per second
Multiple Sclerosis · Spasticity
Primary: MS Walking Scale-12 (MSWS-12) — 72.6; 82.2 units on a scale — p=0.84
Cerebral Palsy · Muscle Spasticity · Children
Primary: Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb — -0.86; -0.97; -0.48 units on a scale — p=0.0029
Leg Spasticity
Primary: Least Squares Mean Change From Baseline to Week 4 in the MAS Score in the Gastrocnemius-soleus Complex (GSC) (Knee Extended) — -0.6; -0.8; -0.5 units on a scale…
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Ankle Score to the End of the DB Phase (Week 12) — -8.513; -5.085 Score*week…
Severe Spasticity
Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140
Muscle Spasticity
Primary: Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale — 4.1; 4.1; -0.81; -0.61 Scores on a Scale
Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Primary: Occurrence of Treatment-Emergent Adverse Events (AEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs) by Injection Cycle, Overall and Related to the…
Stroke · Brain Injuries · Spasticity
Primary: Spastic Hypertonia as Measured by the Ashworth Scale — 2.4; 2.33; 2.36 score on a scale
Post-stroke Spasticity · Spasticity Post-Traumatic Brain Injury
Primary: Assessment of the Long-Term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs) — 140; 97; 47; 21 participants
Cerebral Palsy · Spasticity
Primary: MP: Change From Baseline in Ashworth Scale (AS) in UL Primary Clinical Target Pattern at Week 4 — -0.93; -1.15; -0.96; -1.02 Unit on a scale — p== 0.017
Muscle Spasticity
Primary: Physician Assessment of Success, as Determined by Percentage of Patients Who Achieve Their Principal Active Functional Goal at Week 24 — 40.9; 33.3 Percentage of Patients
Spasticity
Primary: Change From Baseline Contralesional Corticospinal Excitability — 67.88; -37.23 microVolts
Multiple Sclerosis · Spasticity, Muscle
Primary: Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results — 276 Participants
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6 — -1.06; -1.01; -0.80 score on a scale — p=0.010
Spinal Cord Injuries
Primary: Correlation Between Knee Flexor Muscle Modified Ashworth Scale and Insulin Resistance — -0.692; 0.23 correlation coefficient — p=0.006
Cerebral Palsy · Muscle Spasticity · Children
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Reported in the Double Blind (DB) + Open Label (OL) Period. — 177; 5; 91; 151 participants
Pediatrics · Muscle Spasticity · Cerebral Palsy
Primary: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 65.4 percentage of participants
Equinovarus; Acquired
Primary: Self-Selected Velocity (SSV) — 0.41; .48; 0.48; 0.52 m/s
Stroke · Spasticity, Muscle · CVA
Primary: Changes in the H-reflex Amplitude in Response to Nerve Stimulation
Spasticity
Primary: Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score — 0.33; 0.03 score on a scale
Spinal Cord Injuries · Paraplegia · Paraparesis
Primary: Change in Motor Evoked Potential (MEP) Amplitude in the Tibialis Anterior Muscle at the End of Training. — -1.75; -2.01 Amplitude percentage of Mmax
Multiple Sclerosis
Primary: Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks — -1.55; -1.00 units on a scale
Restless Legs Syndrome · Neuropathic Pain
Primary: Percent Change MSNA Burst Frequency From Baseline to 60 Minutes — -29; -24 Percent change MSNA burst frequency
Nervous System Disorders
Primary: Change From Baseline in MAS Score in the Primary Targeted Muscle Group (PTMG) — -0.3; -1.2; -1.4 units on a scale
Spastic Cerebral Palsy
Primary: Change in Normalized Muscle Volume of the Medial Gastrocnemius and the Distal Compartment of the Semitendinosus — -0.08; 0.00; -0.09; -0.01 ml/kg*m